

# Japan Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application, And Segment Forecasts, 2022 - 2030

<https://marketpublishers.com/r/JC73D814CBCCEN.html>

Date: October 2022

Pages: 118

Price: US\$ 5,950.00 (Single User License)

ID: JC73D814CBCCEN

## Abstracts

This report can be delivered to the clients within 2 Business Days

### Japan Contract Development And Manufacturing Organization Market Growth & Trends

The Japan contract development and manufacturing organization market size is expected to reach USD 19.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is anticipated to expand at a CAGR of 6.7% from 2022 to 2030. The main drivers of this market are rising investment by contract development and manufacturing organizations (CDMOs) for capacity expansion, a high geriatric population and growing disease burden in Japan, and low costs associated with outsourcing drug manufacturing and development services.

The COVID-19 pandemic boosted the demand for the CDMO market. Several CDMOs in Japan had tried to improve their capability by expanding their facilities even during the pandemic. For instance, in August 2020, Bushu Pharmaceuticals expanded its facility in the Misato plant in Japan to be dedicated to the storage of temperature-controlled sterile drugs and biologics. Similarly, in July 2020, CMIC Group established a new facility in Japan dedicated to processing development and GMP manufacturing of antibody drugs. Such initiatives by CDMOs in the country are expected to have a positive impact on the market.

The market players are continuously engaging in major strategic initiatives like

expanding their facilities, collaborating, partnerships, new service launches, and mergers & acquisitions. For instance, in May 2020, Catalent, a market leader in clinical supply services, announced plans to buy a clinical packaging facility from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan. By making this purchase, a new clinical GMP production and distribution hub will be created to assist clinical research. Furthermore, in July 2022, Catalent announced that it would be constructing a high-speed blister packaging line in Shiga, Japan. This will be in addition to its automated fill-and-finish production facility.

## Japan Contract Development And Manufacturing Organization Market Report Highlights

The API product segment accounted for the largest revenue share of 80.9% in 2021. The product segment is divided into API and drug product

Based on application, the commercial segment dominated the market in 2021. This is due to the rising demand for generic drugs, and the high burden of chronic diseases are some factors contributing to the growth

The oncology segment is anticipated to register the fastest CAGR of 7.2% during the forecast period, due to the growing number of cancer cases in the country which is improving the demand for new cancer therapeutics

In November 2020, WuXi AppTec expanded its services offered by Cell & Gene Therapy Platform. The platform is now capable of developing, manufacturing, and introducing cell and gene therapies faster and with greater predictability

## Contents

### CHAPTER 1 METHODOLOGY AND SCOPE

- 1.1 Market Segmentation & Scope
  - 1.1.1 Product
  - 1.1.2 Workflow
  - 1.1.3 Application
  - 1.1.4 Estimates And Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
  - 1.3.1 Purchased Database
  - 1.3.2 Gvr's Internal Database
  - 1.3.3 Secondary Sources
  - 1.3.4 Primary Research
  - 1.3.5 Details Of Primary Research
- 1.4 Information Or Data Analysis
  - 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
  - 1.5.1 Approaches Used To Estimate The Market Size
    - 1.5.1.1 Approach 1: Parent Market Analysis
    - 1.5.1.2 Approach 2: Commodity Flow (Company Share Analysis)
- 1.6 Model Details
  - 1.6.1 Commodity Flow Analysis (Model 1)
  - 1.6.2 Volume Price Analysis (Model 2)
- 1.7 List Of Secondary Sources
- 1.8 List Of Abbreviations
- 1.9 Objectives
  - 1.9.1 Objective - 1:
  - 1.9.2 Objective - 2:
  - 1.9.3 Objective - 3:
  - 1.9.4 Objective - 4:

### CHAPTER 2 EXECUTIVE SUMMARY

- 2.1 Market Outlook
- 2.2 Segment Outlook

### CHAPTER 3 JAPAN CDMO MARKET: VARIABLES, TRENDS, & SCOPE

### 3.1 Market Lineage Outlook

#### 3.1.1 Parent market outlook

#### 3.1.2 Ancillary market outlook

### 3.2 Penetration & Growth Prospect Mapping

### 3.3 Market Dynamics

#### 3.3.1 Market Driver Analysis

##### 3.3.1.1 Growing demand for Biopharmaceutical drugs in Japan

##### 3.3.1.2 High geriatric population and growing disease burden in Japan

##### 3.3.1.3 Low cost associated with Outsourcing Drug Manufacturing and Development

services

#### 3.3.2 Market Restraint Analysis

##### 3.3.2.1 Limited outsourcing opted for by big pharma companies

##### 3.3.2.2 Quality Issues While Outsourcing

### 3.4 Japan CDMO Market Analysis Tools

#### 3.4.1 Porter's Five Forces Analysis

#### 3.4.2 PESTEL Analysis

### 3.5 Major Deals & Strategic Alliances Analysis

#### 3.5.1 Expansions

#### 3.5.2 Partnerships and Collaboration

#### 3.5.3 Mergers and Acquisitions

#### 3.5.4 Service and Product Launch

#### 3.5.5 Joint Venture

### 3.6 COVID-19 Impact

## **CHAPTER 4 JAPAN CDMO MARKET: PRODUCT SEGMENT ANALYSIS**

### 4.1 Japan CDMO: Market Share Analysis, 2021 & 2030

### 4.2 Japan CDMO Market: Definition and Scope

### 4.3 API

#### 4.3.1 API market, 2018 - 2030 (USD Million)

#### 4.3.2 Type

##### 4.3.2.1 Traditional Active Pharmaceutical Ingredient (Traditional API)

###### 4.3.2.1.1 Traditional APIs market, 2018 - 2030 (USD Million)

##### 4.3.2.2 HP-API

###### 4.3.2.2.1 HP-API market, 2018 - 2030 (USD Million)

##### 4.3.2.3 Antibody Drug Conjugate

###### 4.3.2.3.1 Antibody Drug Conjugate market, 2018 - 2030 (USD Million)

##### 4.3.2.4 Others

- 4.3.2.4.1 Others market, 2018 - 2030 (USD Million)
- 4.3.3 Synthesis
  - 4.3.3.1 Synthetic
    - 4.3.3.1.1 Synthetic market, 2018 - 2030 (USD Million)
    - 4.3.3.1.2 Solid
      - 4.3.3.1.3 solid market, 2018 - 2030 (USD Million)
      - 4.3.3.1.4 liquid
        - 4.3.3.1.5 liquid market, 2018 - 2030 (USD Million)
    - 4.3.3.2 Biotech
      - 4.3.3.2.1 Biotech market, 2018 - 2030 (USD Million)
  - 4.3.4 Drug
    - 4.3.4.1 Innovative
      - 4.3.4.1.1 Innovative market, 2018 - 2030 (USD Million)
    - 4.3.4.2 Generics
      - 4.3.4.2.1 Generics market, 2018 - 2030 (USD Million)
  - 4.3.5 Manufacturing
    - 4.3.5.1 Continuous manufacturing
      - 4.3.5.1.1 Continuous Manufacturing market, 2018 - 2030 (USD Million)
    - 4.3.5.2 Batch manufacturing
      - 4.3.5.2.1 Batch Manufacturing market, 2018 - 2030 (USD Million)- 4.3 Drug Product
  - 4.3.1 Oral solid dose
    - 4.3.1.1 Oral solid dose market, 2018 - 2030 (USD Million)
  - 4.3.2 Semi-solid dose
    - 4.3.2.1 Semi-solid dose market, 2018 - 2030 (USD Million)
  - 4.3.3 Liquid Dose
    - 4.3.3.1 Liquid Dose market, 2018 - 2030 (USD Million)
  - 4.3.4 Others
    - 4.3.4.1 Others market, 2018 - 2030 (USD Million)

## **CHAPTER 5 JAPAN CDMO MARKET: WORK FLOW SEGMENT ANALYSIS**

- 5.1 Japan CDMO: Market Share Analysis, 2021 & 2030
- 5.2 Japan CDMO Market: Definition and Scope
- 5.3 Clinical
  - 5.3.1 Clinical market, 2018 - 2030 (USD Million)
  - 5.3.2 Commercial
    - 5.3.2.1 Commercial market, 2018 - 2030 (USD Million)

## **CHAPTER 6 JAPAN CDMO MARKET: APPLICATION SEGMENT ANALYSIS**

- 6.1 Japan CDMO Market: Definition and Scope
- 6.2 Japan CDMO: Market Share Analysis, 2021 & 2030
- 6.3 Oncology
  - 6.3.1 Oncology market, 2018 - 2030 (USD Million)
- 6.4 Hormonal
  - 6.4.1 Hormonal market, 2018 - 2030 (USD Million)
- 6.5 Glaucoma
  - 6.5.1 Glaucoma market, 2018 - 2030 (USD Million)
- 6.6 Cardiovascular Disease
  - 6.6.1 Cardiovascular Disease market, 2018 - 2030 (USD Million)
- 6.7 Diabetes
  - 6.7.1 Diabetes market, 2018 - 2030 (USD Million)
- 6.8 Others
  - 6.8.1 Others market, 2018 - 2030 (USD Million)

## **CHAPTER 7 COMPETITIVE LANDSCAPE**

- 7.1 Company Profiles
  - 7.1.1 CORDENPHARMA INTERNATIONAL
    - 7.1.1.1 Company overview
    - 7.1.1.2 Financial performance
    - 7.1.1.3 service benchmarking
    - 7.1.1.4 Strategic initiatives
  - 7.1.2 WuXi AppTec
    - 7.1.2.1 Company overview
    - 7.1.2.2 Financial performance
    - 7.1.2.3 service benchmarking
    - 7.1.2.4 strategic initiatives
  - 7.1.3 Cambrex Corporation
    - 7.1.3.1 Company overview
    - 7.1.3.2 Financial performance
    - 7.1.3.3 Service benchmarking
    - 7.1.3.4 Strategic initiatives
  - 7.1.4 Recipharm AB
    - 7.1.4.1 Company overview
    - 7.1.4.2 Financial performance
    - 7.1.4.3 Service benchmarking

- 7.1.4.4 Strategic initiatives
- 7.1.5 Lonza
  - 7.1.5.1 Company overview
  - 7.1.5.2 Financial performance
  - 7.1.5.3 Service BENCHMARKING
  - 7.1.5.4 Strategic initiatives
- 7.1.6 Catalent, Inc.
  - 7.1.6.1 Company overview
  - 7.1.6.2 Financial performance
  - 7.1.6.3 service benchmarking
  - 7.1.6.4 Strategic initiatives
- 7.1.7 Laboratory Corporation of America Holdings
  - 7.1.7.1 Company overview
  - 7.1.7.2 Financial performance
  - 7.1.7.3 Service benchmarking
  - 7.1.7.4 Strategic initiatives.
- 7.1.8 Thermo Fisher Scientific, Inc
  - 7.1.8.1 Company overview
  - 7.1.8.2 Financial Overview
  - 7.1.8.3 Service benchmarking
- 7.1.9 Samsung BioLogics
  - 7.1.9.1 Company overview
  - 7.1.9.2 Financial Overview
  - 7.1.9.3 Service benchmarking
- 7.1.10 FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
  - 7.1.10.1 Company overview
  - 7.1.10.2 Financial Overview
  - 7.1.10.3 Service benchmarking
  - 7.1.10.4 Strategic initiatives
- 7.1.11 SUMITOMO CHEMICAL COMPANY, LIMITED
  - 7.1.11.1 Company overview
  - 7.1.11.2 Financial performance
  - 7.1.11.3 Service benchmarking
  - 7.1.11.4 Strategic initiatives
- 7.1.12 CMIC HOLDINGS Co., LTD
  - 7.1.12.1 Company overview
  - 7.1.12.2 Financial performance
  - 7.1.12.3 Service BENCHMARKING
  - 7.1.12.4 Strategic initiatives

#### 7.1.13 Bushu Pharmaceuticals LTD.

7.1.13.1 Company overview

7.1.13.2 Financial performance

7.1.13.3 Service benchmarking

7.1.13.4 Strategic initiatives

#### 7.1.14 NIPRO

7.1.14.1 Company overview

7.1.14.2 Financial performance

7.1.14.3 Service benchmarking

#### 7.2 Company Market Share Analysis (2021)



## List Of Tables

### LIST OF TABLES

- Table 1 List of secondary sources
- Table 2 List of abbreviations
- Table 3 Japan pharmaceutical market (USD Thousands)
- Table 4 Top 10 causes of death in Japan
- Table 5 Expansion
- Table 6 Partnership and Collaboration
- Table 7 Merger and Acquisition
- Table 8 Service and Product launch
- Table 9 Joint Venture
- Table 10 ADC Approvals in Japan
- Table 11 Services offered by CordenPharma International is
- Table 12 Services offered by WuXi AppTec
- Table 13 Services offered by Cambrex Corporation
- Table 14 Services offered by Charles River Laboratory
- Table 15 Services offered by Lonza
- Table 16 Services offered by Catalent, Inc
- Table 17 Services offered by Laboratory Corporation of America Holdings
- Table 18 Services offered by Patheon
- Table 19 Services offered by Samsung BioLogics
- Table 20 Services offered by FUJIFILM Diosynth Biotechnologies U.S.A.
- Table 21 Services offered by S-RACMO Co., Ltd
- Table 22 Services offered by CMIC HOLDINGS Co., LTD.
- Table 23 Services offered by Bushu Pharmaceuticals Ltd.
- Table 24 Services offered by Nipro Corporation

## List Of Figures

### LIST OF FIGURES

- Fig. 1 Market research process
- Fig. 2 Information procurement
- Fig. 3 Primary research pattern
- Fig. 4 Market research approaches
- Fig. 5 QFD modeling for market share assessment
- Fig. 6 Market formulation & validation
- Fig. 7 Commodity flow analysis
- Fig. 8 Volume price analysis
- Fig. 9 CDMO market snapshot (2020)
- Fig. 10 CDMO market segmentation
- Fig. 11 Parent market outlook
- Fig. 12 Related/ancillary market outlook
- Fig. 13 Penetration & growth prospect mapping
- Fig. 14 Current & future impact)
- Fig. 15 Current & future impact)
- Fig. 16 Risk associated with outsourcing services
- Fig. 17 Porter's five forces analysis
- Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
- Fig. 19 Segment dashboard
- Fig. 20 Product movement analysis
- Fig. 21 API market, 2018 - 2030 (USD Million)
- Fig. 22 Traditional APIs market, 2018 - 2030 (USD Million)
- Fig. 23 HP-API market, 2018 - 2030 (USD Million)
- Fig. 24 Antibody-drug conjugate market, 2018 - 2030 (USD Million)
- Fig. 25 Others market, 2018 - 2030 (USD Million)
- Fig. 26 Synthetic market, 2018 - 2030 (USD Million)
- Fig. 27 Solid market, 2018 - 2030 (USD Million)
- Fig. 28 Liquid market, 2018 - 2030 (USD Million)
- Fig. 29 Biosimilar approval (2012 - 2021)
- Fig. 30 Biotech market, 2018 - 2030 (USD Million)
- Fig. 31 Innovative market, 2018 - 2030 (USD Million)
- Fig. 32 Generics market, 2018 - 2030 (USD Million)
- Fig. 33 Continuous manufacturing process of tablets
- Fig. 34 Continuous manufacturing market, 2018 - 2030 (USD Million)
- Fig. 35 Batch manufacturing process

- Fig. 36 Batch manufacturing market, 2018 - 2030 (USD Million)
- Fig. 37 Oral solid dose market, 2018 - 2030 (USD Million)
- Fig. 38 Semi-solid dose market, 2018 - 2030 (USD Million)
- Fig. 39 Liquid dose market, 2018 - 2030 (USD Million)
- Fig. 40 Others market, 2018 - 2030 (USD Million)
- Fig. 41 Japan CDMO market workflow outlook: Segment dashboard
- Fig. 42 Japan CDMO market: Workflow movement analysis
- Fig. 43 Japan clinical trial
- Fig. 44 Clinical market, 2018 - 2030 (USD Million)
- Fig. 45 Commercial market, 2018 - 2030 (USD Million)
- Fig. 46 Japan CDMO market synthesis outlook: segment dashboard
- Fig. 47 Japan CDMO market: synthesis movement analysis
- Fig. 48 Oncology market, 2018 - 2030 (USD Million)
- Fig. 49 Hormonal market, 2018 - 2030 (USD Million)
- Fig. 50 Glaucoma market, 2018 - 2030 (USD Million)
- Fig. 51 Cardiovascular disease market, 2018 - 2030 (USD Million)
- Fig. 52 Diabetes market, 2018 - 2030 (USD Million)
- Fig. 53 Others market, 2018 - 2030 (USD Million)
- Fig. 54 Financial Performance of WuXi AppTec
- Fig. 55 Financial performance of Recipharm AB
- Fig. 56 Financial Performance of Lonza
- Fig. 57 Financial performance of Catalent, Inc.
- Fig. 58 Financial Performance of Laboratory Corporation of America Holdings
- Fig. 59 Financial Performance of Thermo Fisher Scientific Inc.
- Fig. 60 Financial Performance of Samsung BioLogics.
- Fig. 61 Financial performance of FUJIFILM Holdings Corp
- Fig. 62 Financial performance of Sumitomo Chemical Company, Limited
- Fig. 63 Financial performance of CMIC HOLDINGS Co., LTD.
- Fig. 64 Financial performance of Nirpo Corporation
- Fig. 65 Japan Company Market Share Analysis (2021)

## I would like to order

Product name: Japan Contract Development And Manufacturing Organization Market Size, Share & Trends Analysis Report By Product (API, Drug Product), By Workflow (Clinical, Commercial), By Application, And Segment Forecasts, 2022 - 2030

Product link: <https://marketpublishers.com/r/JC73D814CBCCEN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JC73D814CBCCEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970